The global study is sponsored by Pfizer Inc. and BioNTech SE.
The companies need participants to be involved in the Phase 2/3 global study of BNT162b2.
The Cleveland VA would be one of 120 clinical investigation sites in the world.
The study is expected to include 30,000 people across the globe.
Study participation priority will be given to Veterans, whether or not they’re enrolled in VA care.
The study is looking for non-pregnant, healthy adults from the ages of 18 to 85 who are at risk for contracting COVID-19.
If you’re interested in participating, call the Cleveland VA Medical Center at (216)791-3800 ext. 65273.